Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in San Sebastian De Los Reyes – page 212

3 196 clinical trials in San Sebastian De Los Reyes, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
San Sebastian De Los Reyes at a glance
3 196
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

3 196 trials in San Sebastian De Los Reyes

Open in trial search

Colorectal cancer metastatic

Not recruiting

Study of MK-4280A (Favezelimab and Pembrolizumab) for Patients with Metastatic Colorectal Cancer After Previous Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Diffuse large B-cell lymphoma+2

Not recruiting

Study of Tisagenlecleucel for Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Novartis Pharma AG

Cardiovascular disorder

Not recruiting

Study on the Effectiveness and Safety of Atorvastatin, Simvastatin, and Fluvastatin in Patients at Risk of Cardiovascular Disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario La Paz

Neoplasm malignant

Not recruiting

A Study of GEN1047 in Patients with Solid Tumors: First Time Use in Humans

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Genmab A/S

Anaemia

Not recruiting

Study on Intravenous Ferric Carboxymaltose for Preoperative Anemia in Patients with Lower Limb Peripheral Artery Disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Ferric Carboxymaltose
  • Sponsor:Asociacion Instituto De Investigacion Sanitaria Biobizkaia

Systemic lupus erythematosus+1

Not recruiting

Study on the Safety and Effects of YTB323, Fludarabine Phosphate, and Tocilizumab in Patients with Severe, Refractory Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Novartis Pharma AG

Graft versus host disease

Not recruiting

Study on the Safety and Effectiveness of Human Alpha1-Proteinase Inhibitor for Preventing Graft-Versus-Host Disease in Patients Undergoing Hematopoietic Cell Transplant.

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:CSL Behring LLC

Malignant melanoma+4

Not recruiting

Study on the Effectiveness and Safety of RO7198457 and Pembrolizumab for Patients with Untreated Advanced Melanoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Autogene Cevumeran
  • Sponsor:Genentech Inc.

Malignant peritoneal neoplasm+2

Not recruiting

Study of Raludotatug Deruxtecan for Patients with Platinum-resistant High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Daiichi Sankyo Inc.

Non-small cell lung cancer

Not recruiting

Study of Selpercatinib for Patients with Early-Stage RET Fusion-Positive Non-Small Cell Lung Cancer After Local Treatment

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Selpercatinib
  • Sponsor:Eli Lilly & Co.

Chronic lymphocytic leukaemia

Not recruiting

Study of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Breast cancer metastatic+1

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with Advanced HER2-Positive Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in San Sebastian De Los Reyes

What the registry says about research in the country

01 Immunology & Allergies

Research focusing on innovative treatments for allergic rhinoconjunctivitis and immune system disorders. Studies include testing immunotherapy effectiveness using specific allergen proteins.

  • Allergic Rhinoconjunctivitis
  • Atopic Dermatitis
  • Myasthenia Gravis

Trials evaluate novel therapeutic approaches for autoimmune conditions and allergic responses.

02 Cardiovascular Health

Comprehensive studies addressing various cardiovascular conditions, including deep vein thrombosis and heart failure management.

  • Pulmonary Embolism
  • Atherosclerotic Disease
  • Hypercholesterolemia

Research focuses on innovative treatments and preventive approaches for cardiovascular complications.

03 Oncology Research

Advanced clinical trials investigating treatments for various cancer types, with emphasis on ovarian cancer and breast cancer therapies.

  • Epithelial Ovarian Cancer
  • HER2+ Breast Cancer
  • Endometrial Cancer

Studies evaluate targeted therapies and maintenance treatments for cancer patients.

04 Metabolic & Systemic Disorders

Research examining treatments for systemic lupus erythematosus and metabolic conditions affecting multiple body systems.

  • Obesity Management
  • Diabetic Neuropathy
  • Liver Disease

Trials focus on innovative therapeutic approaches for chronic systemic conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.